During 2018 Q4 the big money sentiment decreased to 1. That’s change of 0.37, from 2018Q3’s 1.37. 26 investors sold all, 37 reduced holdings as LeMaitre Vascular, Inc. ratio worsened. 46 grew positions while 17 funds acquired positions. Funds hold 14.86 million shares thus 3.37% less from 2018Q3’s 15.38 million shares.
Df Dent & Inc reported 20,127 shs. Fifth Third Bankshares has 0% invested in LeMaitre Vascular, Inc. (NASDAQ:LMAT). State Of Tennessee Treasury Department owns 6,843 shs. Federated Invsts Inc Pa stated it has 508 shs or 0% of all its holdings. Spark Inv Ltd stated it has 0.09% in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Prudential stated it has 0% of its capital in LeMaitre Vascular, Inc. (NASDAQ:LMAT). New York-based Morgan Stanley has invested 0% in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Credit Suisse Ag invested 0% of its capital in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Barclays Public Limited Company owns 6,640 shs. Comerica Bancshares owns 54,794 shs for 0.01% of their capital. Rice Hall James & Associates Lc accumulated 77,305 shs. 12,383 were reported by Intl Group Inc Inc. Us Comml Bank De, Minnesota-based fund reported 3,337 shs. Moreover, Bahl Gaynor has 0.05% invested in LeMaitre Vascular, Inc. (NASDAQ:LMAT) for 209,320 shs. Colonial Tru Advsrs reported 14,407 shs stake.
LeMaitre Vascular, Inc. had 1 insider sale and 0 buys since October 30, 2018. This’s net activity of $558,588.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Ratings Coverage
In total 4 analysts cover LeMaitre Vascular (NASDAQ:LMAT). “Buy” rating has 2, “Sell” are 0, while 2 are “Hold”. (NASDAQ:LMAT) has 50% bullish analysts. 6 are the (NASDAQ:LMAT)’s ratings reports on Apr 6, 2019 according to StockzIntelligence Inc. On Monday, October 8 Canaccord Genuity maintained LeMaitre Vascular, Inc. (NASDAQ:LMAT) with “Hold” rating. In Wednesday, February 20 report Barrington maintained the stock with “Buy” rating. On Wednesday, February 20 Lake Street maintained LeMaitre Vascular, Inc. (NASDAQ:LMAT) with “Hold” rating. On Monday, October 8 the firm has “Buy” rating by Roth Capital given. On Wednesday, February 20 the stock of LeMaitre Vascular, Inc. (NASDAQ:LMAT) has “Hold” rating given by Canaccord Genuity. Listed here are LeMaitre Vascular, Inc. (NASDAQ:LMAT) PTs and latest ratings.
03/03/2019 Broker: BidaskScore Rating: Buy Upgrade
20/02/2019 Broker: Canaccord Genuity Rating: Hold New Target: $25 Maintain
20/02/2019 Broker: Lake Street Rating: Hold New Target: $27 Maintain
20/02/2019 Broker: Barrington Rating: Buy New Target: $30 Maintain
08/10/2018 Broker: Roth Capital Rating: Buy New Target: $34 Upgrade
08/10/2018 Broker: Canaccord Genuity Old Rating: Hold New Rating: Hold Old Target: $40 New Target: $32 Maintain
LMAT touched $30.25 during the last trading session after $0.01 change.Currently LeMaitre Vascular, Inc. is downtrending after 11.92% change in last April 6, 2018. LMAT has also 71,594 shares volume. LMAT underperformed by 16.29% the S&P 500.
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide.The firm is worth $594.32 million. The firm provides angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; carotid shunts to temporarily divert or shut blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and powered phlebectomy devices that enable removal of varicose veins.The P/E ratio is 26.77. It also offers embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude blood flow; and perfusion catheters that temporarily perfuse blood and other liquids into the vasculature.
For more LeMaitre Vascular, Inc. (NASDAQ:LMAT) news published recently go to: Seekingalpha.com, Globenewswire.com, Benzinga.com, Benzinga.com or Fool.com. The titles are as follows: “12 Upcoming Dividend Increases, Including A Dividend King – Seeking Alpha” published on March 15, 2019, “LeMaitre Vascular Acquires Clot Management Business from Applied Medical – GlobeNewswire” on September 26, 2018, “Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker – Benzinga” with a publish date: October 05, 2018, “54 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” and the last “3 Top Healthcare Stocks to Buy in October – Motley Fool” with publication date: October 20, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.